Heterologous protection elicited by candidate monomeric recombinant HIV-1 gp120 vaccine in the absence of cross neutralising antibodies in a macaque model.

Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group.

B cell responses to HIV-1 infection and vaccination: pathways to preventing infection.

Review The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development.

Review Human immunodeficiency virus-1 vaccine design: where do we go now?

Review Why Does the Molecular Structure of Broadly Neutralizing Monoclonal Antibodies Isolated from Individuals Infected with HIV-1 not Inform the Rational Design of an HIV-1 Vaccine?

<i>Propionibacterium acnes</i> Enhances the Immunogenicity of HIVBr18 Human Immunodeficiency Virus-1 Vaccine.

Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques.